Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm + advanced NSCLC.
Ramucirumab + erlotinib is approved and included as a first-line (1L) treatment option in clinical practice guidelines
However, the significant PFS benefit observed in the ramucirumab + erlotinib arm is offset by the toxicity profile of ramucirumab and the need for bimonthly infusions. Pending overall survival results are therefore crucial to assess the true benefit of this combination.
In patients with untrea…